Graphical Summary: Comprehensive assessment of immune phenotype and its effects on survival outcomes in HER2-low versus HER2-zero breast cancer
January 9, 2025
This is a quick graphical summary of recently published study in Breast Cancer: Targets and Therapy.
Investigators evaluated the immune-related gene expression patterns from real-world CGIP data from 129 patients with advanced breast cancer during standard-of-care treatment. There were no significant differences in immune gene expressions such as PD-L1, TIM-3, LAG-3, and TIGIT between HER2-low and HER2-zero breast cancers. HER2-low breast cancers were associated with a higher proportion of estrogen receptor (ER)-positivity. Patients with HER2-low breast cancer have a longer median overall survival than those with HER2-zero cancer, suggesting that there is a prognostic difference between the two, primarily driven by ER expression.